Residency · Residency · Pediatrics
Pediatric Anxiety and Depression
Introduction
Anxiety and depressive disorders are the most common mental health conditions in children and adolescents, with combined prevalence estimates of 15-20%. Anxiety disorders typically emerge in middle childhood, while depression increases markedly during adolescence. Both conditions are frequently underrecognized in pediatric primary care, leading to significant functional impairment in academic, social, and family domains. The U.S. Preventive Services Task Force recommends universal screening for anxiety in children aged 8-18 and universal screening for depression in adolescents aged 12-18. Pediatricians play a critical role in early identification, initial management, and appropriate referral.
Pediatric Anxiety Disorders
Epidemiology
Anxiety disorders are the most common mental health disorders in youth, with a prevalence of approximately 7-10%. The median age of onset is 6 years for specific phobias and 11 years for social anxiety and generalized anxiety disorder. The female-to-male ratio is approximately 2:1 and widens in adolescence. There is a strong familial and genetic component, with heritability of approximately 30-40%.
Classification
Generalized anxiety disorder (GAD) involves excessive, uncontrollable worry about multiple domains including school, health, family, and world events, along with physical symptoms such as muscle tension, restlessness, fatigue, difficulty concentrating, irritability, and sleep disturbance, lasting more than 6 months. Separation anxiety disorder features developmentally inappropriate fear of separation from attachment figures, is common in younger children, and may present with school refusal, somatic complaints, and nightmares about separation. Social anxiety disorder involves marked fear of social situations involving scrutiny by others and avoidance of speaking, eating, or performing in front of others, and may be misinterpreted as shyness. Specific phobias involve intense fear of specific objects or situations (animals, blood, heights, storms) and are clinically significant only when causing avoidance and functional impairment. Selective mutism is the consistent failure to speak in specific social situations (such as school) despite speaking in others (such as at home) and is strongly associated with social anxiety. Panic disorder features recurrent unexpected panic attacks (palpitations, shortness of breath, chest pain, dizziness, derealization, fear of dying) and is more common in adolescents. Agoraphobia involves fear of situations where escape is difficult and often develops after panic attacks.
Clinical Presentation in Children
Somatic complaints are often the primary presenting symptom, including headaches, stomachaches, nausea, chest pain, and dizziness, with thorough medical workup often being negative. Behavioral manifestations include school refusal, clinginess, tantrums, avoidance, reassurance-seeking, and perfectionism. Sleep disturbance may include difficulty falling asleep, nightmares, and reluctance to sleep alone. Children may not articulate "anxiety" and instead describe feeling "sick," "weird," or "scared."
<image>Illustration showing the somatic manifestations of anxiety in children mapped onto a child's body: headaches, throat tightness, chest pain and palpitations, abdominal pain and nausea, trembling, sweating, and muscle tension, with associated anxiety disorder subtypes and their age of typical onset</image>
Evaluation and Screening
The Screen for Anxiety Related Disorders (SCARED) is a 41-item parent and child self-report tool; a score of 25 or greater suggests an anxiety disorder and is validated for ages 8-18. The GAD-7 is a brief 7-item screening tool validated for adolescents. The Spence Children's Anxiety Scale is validated for ages 6-18. Functional impairment should be assessed across academic performance, social relationships, family functioning, and extracurricular participation. Medical causes to rule out include hyperthyroidism, caffeine intake, medication side effects (stimulants, albuterol, corticosteroids), substance use, and cardiac arrhythmia.
Treatment of Anxiety
Cognitive-Behavioral Therapy (CBT) is the first-line treatment for mild to moderate anxiety, with a 60-80% response rate. It includes psychoeducation, cognitive restructuring, relaxation training, and gradual exposure (systematic desensitization). The Coping Cat program is a manualized CBT program for children ages 7-13 with a strong evidence base. SSRIs are first-line pharmacotherapy for moderate to severe anxiety or anxiety not responding to CBT alone. Fluoxetine, sertraline, and fluvoxamine have the most evidence in pediatric anxiety, and the CAMS trial demonstrated that combination CBT plus sertraline was superior to either alone, achieving an 81% response rate. SSRIs should be started at low doses and titrated slowly, with therapeutic effect expected in 4-6 weeks. The FDA black box warning regarding increased risk of suicidal ideation in children and adolescents necessitates close monitoring, especially in the first 4 weeks and after dose changes, though overall benefit typically outweighs risk. Combined CBT plus SSRI is the most effective approach for moderate to severe anxiety. Benzodiazepines are not recommended for routine use in children and should be considered only for short-term use in acute situations such as pre-procedural anxiety.
Pediatric Depression
Epidemiology
The prevalence is 2-3% in children and 8-15% in adolescents, with a sharp increase after puberty. The female-to-male ratio is 1:1 prepubertally, shifting to 2:1 in adolescence. Suicide is the second leading cause of death in youth aged 10-24, with rates having increased significantly since 2007. Risk factors include family history, prior depressive episodes, trauma and adverse childhood experiences, chronic illness, LGBTQ+ identity, social isolation, substance use, and bullying.
Diagnostic Criteria (DSM-5 Major Depressive Disorder)
Diagnosis requires five or more symptoms present during the same 2-week period, representing a change from baseline, and must include either depressed mood or loss of interest/pleasure. The symptoms include depressed mood (or irritability in children and adolescents, a key modification), markedly diminished interest or pleasure (anhedonia), significant weight change or appetite change, insomnia or hypersomnia, psychomotor agitation or retardation, fatigue or loss of energy, feelings of worthlessness or excessive guilt, diminished concentration or indecisiveness, and recurrent thoughts of death, suicidal ideation, or suicide attempt.
Developmental Differences in Presentation
In children, depression more commonly manifests as irritability rather than sadness, along with somatic complaints, behavioral problems, social withdrawal, school refusal, and decline in academic performance. In adolescents, sadness, irritability, boredom, hopelessness, social withdrawal, sleep changes, substance use, self-harm, and suicidal ideation are more typical.
Screening
The PHQ-A (Patient Health Questionnaire for Adolescents) or PHQ-9 Modified for Teens is validated for ages 12-18, with a score of 10 or greater suggesting moderate depression. The Columbia Suicide Severity Rating Scale (C-SSRS) assesses suicidal ideation, intent, plan, and prior attempts. The USPSTF recommends screening all adolescents aged 12-18 for depression, at every well-child visit from age 12 and at any visit where mood symptoms are suspected.
<image>Comparison chart showing the clinical presentation differences of depression in children versus adolescents, with age-specific symptoms, screening tools (PHQ-A scoring guide), and risk factors highlighted, alongside a decision tree for initial management based on severity</image>
Treatment of Depression
For mild depression, active monitoring ("watchful waiting") for 6-8 weeks with supportive counseling, psychoeducation, exercise promotion, and sleep hygiene is appropriate, with escalation if there is no improvement. For moderate to severe depression, CBT and/or interpersonal therapy (IPT-A) combined with pharmacotherapy is recommended. CBT for depression includes cognitive restructuring, behavioral activation, and problem-solving skills over 10-16 sessions and has the strongest evidence among psychotherapies. Interpersonal therapy for adolescents (IPT-A) focuses on interpersonal relationships and role transitions and is effective for adolescent depression.
| Medication | FDA Approval | Indication | Starting Dose | Key Evidence |
|---|---|---|---|---|
| Fluoxetine | Age ≥8 | Depression, OCD | 10 mg/day | TADS trial (61% response) |
| Escitalopram | Age ≥12 | Depression | 5-10 mg/day | Positive RCTs |
| Sertraline | Age ≥6 (OCD) | Anxiety, OCD | 25 mg/day | CAMS trial (55% response) |
| Fluvoxamine | Age ≥8 (OCD) | Anxiety, OCD | 25 mg/day | Positive for anxiety |
| Duloxetine | Age ≥7 (GAD) | Generalized anxiety | 30 mg/day | FDA-approved for GAD |
Regarding pharmacotherapy, fluoxetine is the only FDA-approved SSRI for depression in children age 8 and older and is the first-line medication. Escitalopram is FDA-approved for adolescents age 12 and older. The TADS trial (Treatment for Adolescents with Depression Study) demonstrated that combination fluoxetine plus CBT was most effective (71% response), fluoxetine alone (61%) was superior to CBT alone (43%), and CBT provided additional protection against suicidal ideation. If the first SSRI fails after an adequate trial of 8-12 weeks at therapeutic dose, switching to another SSRI is recommended before considering non-SSRI options. TCAs and paroxetine should be avoided in children and adolescents due to poor efficacy, increased side effects, and suicidality risk.
Suicide Risk Assessment and Safety Planning
Clinicians should ask directly about suicidal thoughts, plans, means, intent, and prior attempts, as asking does not increase risk. Risk factors include prior attempt (the strongest predictor), mental health disorders, substance use, family conflict, bullying, LGBTQ+ identity (particularly transgender youth), access to lethal means, and contagion or exposure to suicide. Protective factors include family connectedness, school engagement, problem-solving skills, cultural and religious beliefs, and access to mental health care. Safety planning is a collaborative process to identify warning signs, coping strategies, sources of support, and means restriction. Means restriction counseling is critical: firearms are the leading method of completed suicide in youth, and counseling on safe firearm storage (locked, unloaded, ammunition stored separately) reduces risk. Medication access should also be addressed.
<image>Safety planning framework for suicidal adolescents showing the step-by-step approach: warning sign identification, coping strategies, social contacts for distraction, adults to contact for help, professional crisis resources (988 Suicide and Crisis Lifeline), and environmental safety (means restriction), presented as a collaborative patient-clinician worksheet</image>
Clinical Pearls
Irritability is often the hallmark of depression in children and adolescents and may be more prominent than sadness. Somatic complaints such as headaches and stomachaches frequently serve as the presenting symptom of both anxiety and depression in children, and these diagnoses should be considered when medical workup is negative. The TADS and CAMS trials provide the strongest evidence for combined therapy (CBT plus SSRI) as the optimal treatment for moderate to severe depression and anxiety in youth. Suicide risk should always be assessed when a child or adolescent screens positive for depression, as direct questioning is essential and safe. Fluoxetine is first-line for pediatric depression, and sertraline and fluoxetine are both first-line for pediatric anxiety; clinicians should start low, go slow, and monitor closely for adverse effects including suicidal ideation.
References
- Walkup JT, Albano AM, Piacentini J, et al. Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood Anxiety (CAMS). N Engl J Med. 2008;359(26):2753-2766.
- March J, Silva S, Petrycki S, et al. Fluoxetine, Cognitive-Behavioral Therapy, and Their Combination for Adolescents with Depression (TADS). JAMA. 2004;292(7):807-820.
- Zuckerbrot RA, Cheung A, Jensen PS, et al. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part I. Practice Preparation, Identification, Assessment, and Initial Management. Pediatrics. 2018;141(3):e20174081.
- US Preventive Services Task Force. Screening for Anxiety in Children and Adolescents. JAMA. 2022;328(14):1438-1444.
